Navigation Links
FDA Approved Treatment for Painful Intercourse (Dyspareunia) Due to Menopause
Date:2/27/2013

r women with dyspareunia due to menopause. Osphena demonstrated significant improvements in painful intercourse as well as on the physical changes of the vagina associated with menopause.

Osphena is an estrogen agonist/antagonist with tissue selective effects. Serious risks of estrogen-alone therapy or Osphena can include increased risk of endometrial cancer, stroke, and deep vein thrombosis (DVT). Osphena should be prescribed for the shortest duration consistent with treatment goals for the individual woman. Women considering treatment for dyspareunia are encouraged to discuss the potential risks and benefits of Osphena with their healthcare provider. Please see below for additional Important Safety Information.

For more information about dyspareunia, VVA and Osphena, please visit http://www.WhatIsDyspareunia.com.

Important safety information for osphena™ (ospemifene) tablets:

Boxed warning: endometrial cancer and cardiovascular disorders

Osphena is an estrogen agonist/antagonist with tissue selective effects. In the endometrium osphena has estrogen agonistic effects. There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogen therapy. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.

The women’s health initiative (WHI) estrogen-alone substudy reported an increased risk of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg], relative to placebo. Osphena 60 mg
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. ASHA Approved Continuing Education Provider HomeCEUConnection.com Announces Two New Live, Interactive Webinars for California Speech-Language Pathologists.
2. EzW2Correction Software Was Approved By SSA To Print W-2C and W-3C On White Paper
3. Newly approved oral medication slows rheumatoid arthritis joint damage
4. Westbridge Agricultural Products Announces that Botector® has been EPA Approved as an Organic Biopesticide to Prevent Gray Mold in Grapes
5. First FDA approved subcutaneous implantable defibrillator available for patients
6. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
7. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
8. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Experimental Vitiligo Treatment Shows Promise in Mice
11. DNDi receives BBVA Foundation award for delivering new treatments for neglected diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 As the Ebola outbreak in ... partners to both purchase critical emergency supplies locally, as well ... Liberia. These supplies will contain materials used to control the ... populated areas of the country. , With a large ... response to the Ebola outbreak in the region. The current ...
(Date:7/29/2014)... Los Angeles, CA (PRWEB) July 29, 2014 ... on the website of Time Magazine titled “From Kim’s ... Want,” Kim Kardashian’s butt is the celebrity ... celebrities and their features include Beyoncé’s butt, Jennifer ... and lips. This information is based on data collected ...
(Date:7/29/2014)... Las Vegas, Nevada (PRWEB) July 29, 2014 ... has reappointed Holland & Hart LLP ’s Connie ... Bar Foundation. She currently serves as President of the Foundation. ... from 2011-2012. , Akridge is a partner at Holland & ... variety of litigation and regulatory/administrative matters to insurance and healthcare ...
(Date:7/29/2014)... 2014) Using quality improvement measures in eight of ... Disease Study Group, researchers have found a way to ... contrast dye. , Currently, 7-15 percent of these patients ... up with kidney injury, which can result in death ... or permanent dialysis, says a study published in the ...
(Date:7/29/2014)... July 29, 2014 CarePoint Health ... have joined our network, CarePoint Health Medical Group. ... Sushma Kaki. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
Breaking Medicine News(10 mins):Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:Reducing kidney injury using a quality improvement method 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3
... 21 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, ... has closed its previously announced public offering (the ... $12.65 million. , The Company issued 73,333,333 Units ... "Offering Price"). The Company concurrently issued an additional ...
... Couples using assisted reproductive technology should be made aware, ... -- Compared to naturally conceived twins, those conceived through ... hospitalized and admitted to neonatal intensive care, finds a ... for all twins born in Western Australia between 1994 ...
... New White Paper Outlines Possible Ways to Improve ... Today, during a Partnership to Fight Chronic ... researchers Michael J. O,Grady, Ph.D., and James C. ... Projections for Diabetes and other Chronic Diseases: The ...
... Indicator of Demand for Well-Priced New and Refurbished ... Despite numerous negative earnings announcements, the demand ... to be robust during the current economic downturn. ... refurbished ultrasound solutions, reported a 118 percent increase ...
... May 21 CPC of America, Inc. (OTC Bulletin ... patent of a synthetic sealant for specific application to ... development and testing of the MedClose(TM) VCS, which is ... diagnostic and interventional procedures. In addition, CPC is ...
... May 21 Genomic Health, Inc. (Nasdaq: ... results from three studies at the American Society of ... - June 2, 2009, at the Orange County Convention ... widely-adopted Onco type DX(R) breast cancer test, which ...
Cached Medicine News:Health News:Response Biomedical Closes $12.65 million Unit Offering 2Health News:Response Biomedical Closes $12.65 million Unit Offering 3Health News:Response Biomedical Closes $12.65 million Unit Offering 4Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3
(Date:7/29/2014)... ST. LOUIS, July 29, 2014  Express Scripts Holding ... quarter net income attributable to Express Scripts stockholders of ... per diluted share, as detailed in Table 4, was ... "We are well positioned to serve our clients with ... and to improve the health outcomes of our members," stated ...
(Date:7/29/2014)... 2014  EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 7, 2014 at 11:00 AM Eastern Time ... June 30, 2014 and to provide a business update. ... quarter conference call may be accessed by dialing (877) ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
... (NYSE: BT ) shared its vision of ... cloud computing strategies to pharma research at the Bio-IT ... This vision reflects BT,s strong capabilities and increasing specialization ... world,s leading pharmaceutical companies rely on BT to support ...
Cached Medicine Technology:Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2BT Pushes for R&D Innovation at Bio-IT World Conference 2BT Pushes for R&D Innovation at Bio-IT World Conference 3
LUMIGAN® is a powerful eye drop medication for lowering IOP. IOP is short for intraocular pressure or eye pressure. LUMIGAN® is the first in a new class of medication....
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% is medication in the form of an eye drop that is used to lower the pressure inside your eye(s), also referred to as intraocular pressu...
Medicine Products: